Kedar Upadhye, global CFO of Cipla, says the company has received approval for the Seretide MDI inhaler. This is a market with a $200 million size as Cipla will be the second generics player in the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback